0001415889-23-002944.txt : 20230221 0001415889-23-002944.hdr.sgml : 20230221 20230221181202 ACCESSION NUMBER: 0001415889-23-002944 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230216 FILED AS OF DATE: 20230221 DATE AS OF CHANGE: 20230221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sorg Elaine K. CENTRAL INDEX KEY: 0001832571 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 23649867 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-02212023_110252.xml X0306 4 2023-02-16 0001551152 AbbVie Inc. ABBV 0001832571 Sorg Elaine K. 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false SVP, US COMMERCIAL OPERATIONS Common Stock, $0.01 par value 2023-02-16 4 A 0 29410 0 A 47286 D Common Stock, $0.01 par value 2023-02-16 4 A 0 6861 0 A 54147 D Common Stock, $0.01 par value 2023-02-16 4 A 0 4658 0 A 58805 D Common Stock, $0.01 par value 2023-02-16 4 A 0 3874 0 A 62679 D Common Stock, $0.01 par value 2023-02-21 4 M 0 15321 105.92 A 78000 D Common Stock, $0.01 par value 2023-02-21 4 S 0 6901 150.74 D 71099 D Common Stock, $0.01 par value 2023-02-21 4 S 0 8420 151.29 D 62679 D Option (Right to Buy) 149.62 2023-02-16 4 A 0 13166 0 A 2024-02-16 2033-02-15 Common Stock 13166 13166 D Option (Right to Buy) 105.92 2023-02-21 4 M 0 15321 105.92 D 2022-02-18 2031-02-17 Common Stock 15321 7660 D Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.53, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,389 on February 16, 2024, 4,389 on February 16, 2025, and 4,388 on February 16, 2026. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Steven L. Scrogham, attorney-in-fact for Elaine K. Sorg 2023-02-21